Nanovibronix Inc (NASDAQ:NAOV) Shares Shorted Strengthened By 2.41%

NanoVibronix, Inc. (NASDAQ:NAOV) Corporate Logo

Nanovibronix Inc (NASDAQ:NAOV) noted an increase of 2.41% in short interest. In April was announced NAOV’s total 8,500 short interest by FINRA. The 8,300 previous shares are up with 2.41%. Previous NAOV’s position will need 5 days to recover. It has 1,900 average volume. Nanovibronix Inc float short is 0.99%.

At traded at $4 lastly.Since April 8, 2018 it’s 0.00% down thus . NAOV underperformed by 4.37% the S&P500.

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target wound healing and pain therapy.The firm is worth $27.16 million. The Company’s products include WoundShield, a patch therapeutic ultrasound device, which facilitates tissue regeneration and wound healing; PainShield, a disposable patch therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and UroShield, an ultrasound product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.Last it reported negative earnings. The firm sells its products in the United States, Israel, Europe, India, and internationally through distributor agreements.

For more NanoVibronix, Inc. (NASDAQ:NAOV) news published briefly go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Barrons.com or Nasdaq.com. The titles are as follows: “Stock Market News For Nov 27, 2018 – Nasdaq” published on November 27, 2018, “Stock Market News For Nov 7, 2018 – Nasdaq” on November 07, 2018, “Stock Market News For Nov 8, 2018 – Nasdaq” with a publish date: November 08, 2018, “The Dow Falls 101 Points, but Did You See the Nasdaq? – Barron’s” and the last “Stock Market News For Nov 8, 2017 – Nasdaq” with publication date: November 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.